Table 5.
Percent Change from Baseline in Whole Body Composition by DEXA in STARTMRK
Raltegravir | Efavirenz | |||||
---|---|---|---|---|---|---|
Week | N | Baseline Mean (gm) | Mean % Change†(95% CI) | N | Baseline Mean (gm) | Mean % Change†(95% CI) |
0 | 55 | 20408.54 | 56 | 17542.25 | ||
48 | 40 | 20095.34 | 18.10 (6.22, 29.98) | 46 | 17776.56 | 19.99 (12.42, 27.57) |
96 | 37 | 21487.02 | 19.63 (3.26, 36.01) | 38 | 17566.83 | 21.04 (12.16, 29.92) |
N = Number of patients in the treatment group.
Mean % change from baseline and are based on the measurements of the patients who were measured at baseline and the time point assessed.
The DEXA re-scan (for the baseline visit) values were taken as the baselines for 7 patients and clinically deemed acceptable, when the original baseline scan readings were not available.
Note: MK-0518 and Efavirenz were administered with tenofovir/emtricitabine.